317 related articles for article (PubMed ID: 25109961)
1. Overcoming bortezomib resistance in multiple myeloma.
Murray MY; Auger MJ; Bowles KM
Biochem Soc Trans; 2014 Aug; 42(4):804-8. PubMed ID: 25109961
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
3. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
4. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
5. Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.
Škrott Z; Cvek B
Crit Rev Oncol Hematol; 2014 Nov; 92(2):61-70. PubMed ID: 24890785
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M
Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
[TBL] [Abstract][Full Text] [Related]
9. [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
Kikuchi J; Furukawa Y
Nihon Rinsho; 2015 Jan; 73(1):57-61. PubMed ID: 25626305
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
12. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Richardson PG; Hideshima T; Anderson KC
Cancer Control; 2003; 10(5):361-9. PubMed ID: 14581890
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitor for treatment of multiple myeloma.
Ahmad K
Lancet Oncol; 2005 Aug; 6(8):546. PubMed ID: 16094754
[No Abstract] [Full Text] [Related]
14. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
15. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
16. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
Manochakian R; Miller KC; Chanan-Khan AA
Oncologist; 2007 Aug; 12(8):978-90. PubMed ID: 17766658
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
Moreau P; Cavallo F; Leleu X; Hulin C; Amiot M; Descamps G; Facon T; Boccadoro M; Mignard D; Harousseau JL
Leukemia; 2011 May; 25(5):872-4. PubMed ID: 21321571
[No Abstract] [Full Text] [Related]
19. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
[TBL] [Abstract][Full Text] [Related]
20. Role of bortezomib for the treatment of previously untreated multiple myeloma.
Mateos MV
Expert Rev Hematol; 2008 Oct; 1(1):17-28. PubMed ID: 21083004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]